Infection with human immunodeficiency virus (HIV) has become pandemic since its first documentation in 1981 and is a major public health concern (11). HIV antibody testing is critical for the diagnosis and counseling of HIV-infected persons, the monitoring of trends in HIV prevalence, and the evaluation of the effectiveness of HIV prevention programs (5, 12 ). An unprecedented number of tests for the detection of HIV antibodies are available. In some kits, improved sensitivity is frequently accompanied by a decreased specificity. This has been of particular concern with the introduction of test kits that detect all isotypes of antibodies, such as those based on antibody capture by antigens on a solid phase with labeled antigens as the detecting reagents (4, 8) .
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In resource-poor developing countries, the surveillance and diagnosis of HIV infection are major challenges (15) . The conventional algorithm for HIV diagnostic testing consists of screening with enzyme immunoassays followed by confirmation with a Western blot test. Moreover, a double enzymelinked immunosorbent assay (ELISA) without Western blotting has been accepted as the customary screening assay for HIV infection (18) . Because of the high cost of the Western blot test, it has not been affordable in a number of laboratories in developing countries (1) . Rapid screening for HIV infection performed on-site with tests that do not require expensive laboratory infrastructure or highly skilled personnel helps with the diagnoses of patients in emergencies (13) . The present study has been designed to evaluate five different commercially available diagnostic ELISA kits, and also a rapid test kit, for their performance in diagnosing HIV infection.
MATERIALS AND METHODS
This study was carried out at the Y. R. Gaitonde Centre for AIDS Research and Education (YRG CARE) in Chennai, India; it is a referral center for voluntary counseling and testing (VCT) in South India. A total of 264 specimens (plasma and serum) collected from VCT clients were tested using various commercial HIV ELISA kits, and the positive specimens were confirmed by Western blot analysis (Genetic Systems HIV-1 Western blot; Bio-Rad Laboratories, Redmond, WA). The following commercially available ELISA kits were employed in this study: Enzaids HIV 1ϩ2 (Span Diagnostics Ltd., Surat, India), HIV-CheX (Xcyton Diagnostics Ltd., Bangalore, India), Murex HIV-1.2.0 (Murex Biotech Limited, Dartford, United Kingdom), Genscreen HIV 1/2 version 2 (Bio-Rad Laboratories, France), and Vironostika HIV Uni-Form II Ag/Ab (BioMérieux, The Netherlands). Along with these, a rapid test kit, CombAids RS Advantage (Span Diagnostics Ltd., Surat, India), was also evaluated. A double-blind format was adopted in order to conceal patient information from the testing personnel. One staff member generated duplicate numbers for specimens at the specimen processing section; a second staff member generated plate maps and performed the tests. Finally, the results were analyzed by both personnel. The kits were stored under cold conditions at all times, and all of the tests were performed according to the manufacturer's instructions. An optical density higher than the cutoff value, obtained per the manufacturer's instructions, was considered a positive result, and an optical density lower than the cutoff value was considered a negative result. Sensitivity, specificity, predictive values, and efficiency were calculated using the Western blot results as the standard. A Western blot was considered positive for HIV type 1 (HIV-1) if any two of the following viral proteins were present: p24, gp41, and gp120/160 (per the manufacturer's instructions). We have calculated the performance characteristics of all the kits using formulae given elsewhere (17) .
The kits were also evaluated with the following known specimens: 100 Western blot-confirmed HIV-positive specimens (Genetic Systems HIV-1; Bio-Rad Laboratories), 100 HIV-negative specimens (U.S. FDA-approved ELISA; Genetic Systems HIV-1/2 PLUS O), 4 HIV-II-positive specimens (confirmed by NEW LAV BLOT II; Bio-Rad Laboratories, France), and 9 in-house seroconversion specimens. Six specimens from Boston Biomedica, Inc. (BBI panel), Boston, Mass., were tested with only two kits (Enzaids and Murex) due to insufficient specimen volume. Of the six BBI panel specimens, four were 0, 9, 11, and 20 days old, and the others were known positive specimens for HIV-2 and HIV-1 group O, respectively. We were unable to include the Vironostika kit due to the unavailability of funding.
RESULTS
As far as the known specimens are concerned (Table 1) , all of the specimens which contained antibodies to HIV-1 were correctly identified by all of the kits except HIV-CheX, which was unable to detect 11 HIV Western blot-positive specimens, thus resulting in reduced sensitivity. All of the kits correctly identified negative specimens. All of the nine in-house seroconversion specimens were identified as positive by all of the kits except HIV-CheX, which recorded two specimens as negative. All of the in-house specimens of HIV-2 were identified as positive by all of the kits. From the BBI seroconversion panel, Murex detected all six specimens, while Enzaids did not detect the two initial specimens (i.e., 0 and 9 days). Both kits showed positive results for the HIV-2 and HIV-1 group O specimens from the BBI panel.
The results of the 264 VCT specimens used for the evaluation of commercially available kits for the diagnosis of HIV infection are summarized in Table 2 . It is clearly evident that the Enzaids, Murex, Vironostika, and CombAids test kits gave uniform results with good sensitivity and specificity. All four of these kits exhibited one false positive ( Table 3 ). The results of the HIV-CheX and Genscreen tests were not satisfactory due to their poor performance characteristics. Of the 264 specimens tested by Western blotting, one was indeterminate in exhibiting the p24 band, positive in the Murex kit, and negative in all of the other kits, and this specimen was removed from the analysis due to the unavailability of PCR results. A total of 19 specimens were found to be discordant with the Western blot results, which can be considered an inherent limitation of the respective test kits (Table 3 ). Many false positives and false negatives were observed in the Genscreen and HIV-CheX tests, respectively.
DISCUSSION
In the present study, we have evaluated the performance of two domestic and three imported HIV ELISA kits. We have also included a domestic rapid HIV kit with the ELISA kits. In-house seroconversion panel (n ϭ 9) 9 9 9 7 9
a The two initial specimens, from 0 and 9 days, were not detected. b ND, not done. Poor performance was seen with the Genscreen and HIVCheX kits. The Murex test detected antibodies in all of the specimens in the BBI panel, and this result coincided with those of other studies (2, 7). Concordant results were obtained with the in-house seroconversion specimens with all of the kits except HIV-CheX. In other studies, the Genscreen kit demonstrated worse performance characteristics than other kits, as it could not detect either HIV-1 group M, subtypes A and B, or HIV-1 group O antigens in the range tested (10 to 125 pg/ml) (7, 19, 20) . This result matches the poor performance shown in our study, as many false positives were detected. Even though Western blot analysis is a confirmatory test (3, 9) , the combination of two or more antibody screening assays, which use different antigenic bases, may be more sensitive and specific than Western blotting (3, 8-10, 16, 18) . According to our study, for double ELISA combinations, the recommended kits are the Enzaids, Murex, and Vironostika kits. Using the HIV-CheX or Genscreen kit with any other kit would be an ineffective combination. One notable issue here is the discordance between the results of two assays (6, 8, 14) , which can be resolved if better kits are used. Hence, this kind of evaluation gains importance for determining a better choice of kits. It is also noted that the sera of up to 40% of uninfected persons gave indeterminate Western blot results (3, 8, 9) .
As far as patients are concerned, discordant results may have the consequence of inducing psychological stress while the patient is waiting for confirmatory testing and may also result in additional expenses. False-positive results could cause considerable unnecessary anxiety and mental trauma for the patients. This outcome may also lead to the unnecessary waste of valuable blood in blood banks. In this evaluation, we found a large number of false positives with the Genscreen kit. The damage caused by false-negative test results is also a serious problem, as a person who is falsely tested to be negative may continue the transmission of the virus. The possibility of transfusing blood after such a false-negative test also underlines the need for high-quality, sensitive ELISAs. In this evaluation, we found false-negative results with the HIV-CheX kit, leaving the population under the threat of silent HIV transmission.
Even though this study did not concentrate on a rapid HIV detection assay, we included the CombAids rapid assay in order to evaluate its comparative performance. The performance of this rapid assay was found to be comparable to that of ELISA in terms of sensitivity and specificity. Therefore, the CombAids assay can be a useful tool for the prompt screening of patient specimens at point-of-care facilities, reference laboratories (15) , prenatal clinics, and emergency rooms located in regions where laboratorial infrastructure is either not present or not well outfitted. We do not have the clinical characteristics of the patients, such as concomitant infections or use of chemotherapeutic or recreational drugs, to compare with our results. Due to insufficient quantities of specimens, we used the seroconversion panel only for the Murex and Enzaids tests. One test specimen, found to be positive by only the Murex HIV-1.2.0 test, was indeterminate by Western blotting with the p24 band. Due to the lack of availability of PCR assay and/or follow-up specimen results for this individual, we were unable to resolve the conflicting serology for this specimen; hence, it was removed from the analysis. Also due to unavailability of funds, we did not use the Vironostika kit to test known specimens. These are some of the limitations of this study.
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